About Shire Viropharma (NASDAQ:VPHM)
ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: Pharmaceuticals
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:VPHM
- CUSIP: 92824110
- Web: www.viropharma.com
- Outstanding Shares: 65,860,000
Frequently Asked Questions for Shire Viropharma (NASDAQ:VPHM)
What is Shire Viropharma's stock symbol?
Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."
How were Shire Viropharma's earnings last quarter?
Shire Viropharma Inc (NASDAQ:VPHM) posted its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.15. The biotechnology company had revenue of $113 million for the quarter, compared to analysts' expectations of $113.35 million. The firm's revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. View Shire Viropharma's Earnings History.
Who are some of Shire Viropharma's key competitors?
Some companies that are related to Shire Viropharma include Icon Plc (ICLR), Covance (CVD), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Anacor Pharmaceuticals (ANAC), INC Research Holdings (INCR), Puma Biotechnology (PBYI), FibroGen (FGEN), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND), Blueprint Medicines Corporation (BPMC) and Ironwood Pharmaceuticals (IRWD).
How do I buy Shire Viropharma stock?
Shares of Shire Viropharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Shire Viropharma?
Shire Viropharma has a market capitalization of $3.3 billion.
How can I contact Shire Viropharma?
Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.
MarketBeat Community Rating for Shire Viropharma (NASDAQ VPHM)MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Shire Viropharma (NASDAQ:VPHM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Shire Viropharma (NASDAQ:VPHM)
Analysts' Ratings History for Shire Viropharma (NASDAQ:VPHM)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Shire Viropharma (NASDAQ:VPHM)
Earnings History by Quarter for Shire Viropharma (NASDAQ VPHM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/24/2013||Q313||$0.05||$0.20||$113.35 million||$113.00 million||View||N/A|
|8/1/2013||Q2 2013||$0.01||$0.15||$105.06 million||$104.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.04||$0.15||$108.47 million||$107.00 million||View||N/A|
|2/27/2013||Q4 2012||$0.03||$0.10||$103.06 million||$106.50 million||View||N/A|
Earnings Estimates for Shire Viropharma (NASDAQ:VPHM)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Shire Viropharma (NASDAQ:VPHM)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Shire Viropharma (NASDAQ:VPHM)
Latest Headlines for Shire Viropharma (NASDAQ VPHM)
Shire Viropharma (NASDAQ VPHM) Chart for Saturday, November, 18, 2017